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Paediatric clinicians are often forced to use medicines in an off-
label manner, as pharmaceutical companies tend to avoid the 
expense of developing paediatric formulations of established 
adult medicines unless the market demand is high. Although 
the USA’s Food and Drug Administration (FDA) and European 
Medicines Agency (EMEA) now mandate that a paediatric plan 
be put in place for essential medicines, paediatric formulations 
are still often not appropriate. A prime example is the Aluvia 
paediatric tablet (100/25 mg) that contains a dose that is too 
large for most young children. The alternative of using adult 
formulations in an off-label manner leads to questions around 
dosing accuracy, bioavailability, efficacy and safety. Studies are 
therefore under way to investigate the bioavailability of cut 
or crushed Aluvia tablets in children (Dr Brookie Best, Center 
for AIDS Research, University of California, San Diego, USA 
– personal communication).
Stavudine is an important component of the first-line 
antiretroviral regimen used in the public sector in South Africa.1 
The proprietary paediatric liquid formulation of stavudine 
(Zerit; Bristol-Myers Squibb) requires a specific volume (202 
ml) of purified water for reconstitution. Once reconstituted, 
the solution has to be refrigerated at 4°C to maintain stability,2 
and is only stable for 1 month when refrigerated. Adult 
stavudine capsules, however, are stable at room temperature 
for 2 years.3 In an attempt to overcome the logistical problems 
associated with supplying the proprietary solution to children 
in rural areas, the Department of Health recommended that 
caregivers without access to a refrigerator should instead 
open a stavudine capsule and mix the contents in a specific 
volume of tap water.1 Caregivers are to mix the contents of a 
capsule in 5 ml water and then withdraw the required fraction 
of the solution (usually 2.5 ml) with a syringe. If there is any 
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Introduction. If a caregiver does not have access to a refrigerator, the South African National Department of Health advises 
that stavudine adult capsule formulations be employed using the off-label ‘opened capsule’ dosing method. The accuracy of 
this dosing method has not previously been validated.
Aim. To assess the accuracy of the off-label opened capsule method for stavudine dosing in infants and children. In addition, we 
assessed the relative ease of dispersion of generic and original capsule preparations in water to determine which preparations, 
if any, are suitable for the off-label opened capsule dosing method. 
Method. We evaluated 10 Zerit (Bristol-Myers Squibb), 5 Stavudine (Aspen), and 5 Stavir (Cipla) capsules. Each capsule was 
dispersed in 30 ml water, creating 20 separate solutions. Timed dispersion of each generic was compared with that of the 
original (Zerit). Each solution was then centrifuged to remove sediment, and the concentration of active drug (mg/ml) was 
analysed by high-performance liquid chromatography.
Results. The ease of dispersion of the contents of Aspen Stavudine capsules was equivalent to that of Zerit, and resulted in a 
mean recovery of active drug from solution of over 97%, confirming the accuracy of this dosing method. The contents of Stavir 
capsules, however, were extremely difficult to disperse in water despite prolonged agitation; consequently, the recovery of 
active drug from the solution was reduced.
Conclusion. The accuracy of the off-label opened capsule dosing method for stavudine is acceptable. There is no need to instruct 
caregivers to include sediment in the aliquot given to the infant. However, studies that confirm adequate bioavailability and 
efficacy are needed. In addition, it is important to avoid supplying generic capsules the contents of which do not disperse easily 
in water, as this may lead to a significant reduction in the amount of active drug that a child receives.
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delay, the caregiver is advised to re-agitate 
the mixture carefully to re-suspend the 
sediment that collects at the bottom of the 
container, before drawing up the aliquot 
for the child. This administration method 
has been termed the ‘opened capsule’ 
dosing method.
There are no published data on the 
accuracy of the opened capsule dosing 
method advocated by the South African 
Department of Health for stavudine 
dosing in infants and children. The opened 
capsule method is off-label. Manufacturers 
do not recommend that capsules be opened 
or made into a suspension in water before 
consumption.2,3 The contents of stavudine 
capsules do not dissolve completely, and 
rapidly form a sediment at the bottom of 
the container. There is no guarantee that 
half the volume of such a solution reliably 
contains half the dose. The accuracy of 
this practice needs to be assessed. In 
addition, as generic products are widely used in the public 
programme, the ease of dispersion of the various generic 
capsule preparations should be independently compared.
The aim of this study was to assess the accuracy of the off-
label opened capsule dosing method for stavudine in infants 
and children. In addition, we assessed the relative ease of 
dispersion of generic and original capsule preparations in 
water to determine which preparations, if any, are suitable for 
off-label opened capsule dosing.
Method
We compared two of the commercially available generic adult 
stavudine capsules (Aspen Stavudine and Cipla Stavir ) with 
the original preparation Zerit (Bristol-Myers Squibb). We 
evaluated 10 Zerit, 5 Aspen Stavudine and 5 Stavir capsules. 
The generic capsules were obtained from the Western Cape 
Department of Health antiretroviral depot. The Stavir capsules 
were from lot X70669 (expiry date 06/2009). The Zerit capsules 
were purchased commercially by the Children’s Infectious 
Diseases Clinical Research Unit (KID-CRU) pharmacy, 
Tygerberg Children’s Hospital.
Each capsule was stated to contain 30 mg of active drug, and was 
dispersed in 30 ml water, thus creating 20 separate solutions. 
Rather than use the technical dispersion method for capsules 
described in the British Pharmacopoeia,5 we intentionally used 
the manual dispersion technique taught to caregivers in public 
sector clinics. However, we used a larger volume of water than 
described in the National Department of Health guidelines to 
avoid amplifying the effect of any inaccuracy from the manual 
technique, ensuring that the recovery of active drug from each 
solution could be fairly compared. All solutions were made 
up by the same investigator using the same standardised 
method. Timed dispersion of each generic was compared with 
the original (Zerit). Each solution was then centrifuged, and 
the concentration of active drug (mg/ml) was analysed by 
high-performance liquid chromatography (HPLC). Statistical 
analysis was performed by JMP statistics software, version 7.0 
(SAS Corporation, California).
Laboratory method
Undissolved particulate matter 
was separated from the solution by 
centrifuging and was then discarded. 
The stavudine-containing samples were 
analysed using a Hewlett Packard 1100 
series high-performance binary liquid 
chromatograph (Agilent Technologies, 
Waldbronn, Germany) with an Eclipse 
(XDB-C18) Zorbax analytical column (15 
mm x 4.6 mm ID, 5 micron particle size). 
This was preceded by a 30 mm x 2.1 mm 
ID C18-guard column (40 micron particle 
size). The temperature was maintained 
at 40oC and the flow rate at 1 ml/min. 
The mobile phase consisted of a mixture 
of two solvents: A (50 mM KH2PO4, pH 
5.42) and B (acetonitrile:isopropanol 4:1 
(v/v)). The following gradient was used: 
0 - 1 minute = isocratic at 5% B; 1 - 7.5 
minutes = linear increase to 15% B; 7.5 - 10 
minutes = isocratic at 15% B. All reagents 
used for the mobile phase were HPLC grade (E Merck, 
Darmstadt, Germany) and were filtered through a 0.45 micron 
filter to remove particular matter. De-ionised water was used 
for the preparation of all aqueous solution and standards. Two 
hundred µl of the sample was diluted with 800 µl of de-ionised 
water to avoid detector overload and to ensure that detector 
response remained within linear range of the calibration 
curve. Aliquots of 5 µl from each sample were injected onto 
the column. The variable wave detector was set at 266 nm. 
The retention time of stavudine was 4.92 minutes, with a total 
run time of 7.5 minutes. Three minutes was allowed for the 
column to stabilise at 5% B before each subsequent injection. 
Recording and integration of the peaks were performed by 
means of an Agilent Chem Station (Agilent Technologies, Santa 
Clara, California). Spiked standards were prepared from pure 
stavudine compound (Aspen Laboratories, batch # 13961 V), 
and were randomly included in each batch over the expected 
concentration range. The calibration curve of triplicate 
samples was found to be linear over the entire concentration 
range (R2=0.999915) (Fig. 1). The limits of quantification were 
0.5 - 2 mg/ml.
Results
All three capsule preparations produced a sediment that 
rapidly collected at the bottom of the container when the 
contents of a capsule were mixed in water (Fig. 2).
The Medicines Control Council requires that the content of 
active ingredient in any medicinal preparation should lie 
within 10% of the label claim.4 The contents of Zerit capsules 
dispersed easily with minimal agitation, resulting in a mean 
recovery of active drug from solution of over 97% (Table I). The 
ease of dispersion of the contents of Aspen Stavudine capsules 
was equivalent to that of Zerit, resulting in a mean recovery 
of active drug from solution of over 97% (Table I). The minor 
difference in recovery of active drug from solution when 
comparing Zerit with Aspen Stavudine was not statistically 
significant (p=0.8272), suggesting that these two drugs are 
likely to be equivalent when given to children using the off-
label opened capsule administration method.
The lack of appropriate 
paediatric antiretro- 
viral preparations is  
a global problem.
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The contents of Stavir capsules were extremely difficult to 
disperse in water despite prolonged agitation. Their contents 
appeared to be partially hydrophobic, floating persistently 
on the meniscus of the sample. Consequently, recovery of 
active drug was reduced (Table I). However, because of the 
small sample size, the difference in recovery of active drug 
from solution when comparing Zerit with Stavir did not reach 
statistical significance (p=0.1730).
Discussion
The lack of appropriate paediatric antiretroviral formulations 
is a global problem.6,7 The use of liquid formulations may 
not be feasible in rural areas, as they are heavy and difficult 
to transport, have a short shelf-life, and may require 
refrigeration. Paediatric clinicians are often forced to employ 
an adult formulation in rural areas where the logistic obstacles 
to supplying a liquid formulation are prohibitive. Therefore, 
where suitable, solid paediatric antiretroviral formulations 
are not available, the World Health Organization (WHO) has 
recommended that off-label use of adult formulations should 
be investigated.8
When a drug is employed in an off-label manner in children, 
the clinical implications should be carefully considered. The 
dosing accuracy, bioavailability, efficacy and safety of using 
an adult formulation in children all require investigation. 
In addition, off-label use of adult formulations requires 
manipulation that may affect the dosage, such as cutting adult 
tablets or emptying the contents of capsules into water and 
then administering a specific volume. These activities are time-
consuming and may affect adherence negatively. However, 
once tested, the off-label use of adult formulations in children 
can be extremely effective, as has become well established in 
fields such as paediatric cardiology.9
In our study, we found that, when the contents of a stavudine 
capsule were dispersed in water, practically all the active drug 
was found in the supernatant; by inference, only a negligible 
amount remains in the visible sediment. It is probable that the 
sediment is composed only of the pharmacologically inactive 
excipients of the capsule formulation, such as magnesium 
stearate. This information is important to caregivers, who do 
not need to re-suspend sediment when giving the solution to 
their infant. It is therefore unnecessary to instruct caregivers 
to agitate the mixture before withdrawing the aliquot to be 
given to the child. This important finding will help to simplify 
a technique that is at best difficult for elderly caregivers, who 
struggle with the dexterity and precision needed for this 
method.
We found a significant difference in the ease of dispersion of 
the capsule contents of the two generic capsule preparations, 
which may lead to a significant reduction in the amount of 
active drug that a child receives when Stavir capsules are 
supplied to caregivers. However, the opened capsule dosing 
method is off-label, and our data do not permit comment 
on the absorption of active drug from intact capsules of 
any of the preparations tested. There is a need to perform a 
pharmacokinetic study to confirm that stavudine administered 
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Fig. 2. Incomplete dissolution of stavudine capsules in water (Z = 
Zerit, A = Aspen Stavudine, B = Stavir).
Table I. ComparIson of The DIspersIbIlITy anD aCTIve Drug ConTenT of mIxTures maDe 
wITh orIgInal anD generIC branDs of sTavuDIne Capsules usIng The ‘openeD Capsule’  
DosIng meThoD
 Zerit aspen stavudine stavir
 (n=10) (n=5) (n=5)
Obtained stavudine concentration in the constituted solution (mg/ml)
(mean ± SD) 0.971±0.022 0.974±0.018 0.938±0.070
Expected stavudine concentration in the constituted solution (mg/ml) 1.000 1.000 1.000
Stavudine recovered from the solution (%) (mean ± SD) 97.12±2.18 97.39±1.86 93.77±6.96
Percentage deviation from the expected concentration (%) -2.86 -2.61 -6.23
Time taken for complete dissolution of stavudine capsule in water (s) 18 18 >65 
SD = standard deviation; expected stavudine concentration in the constituted solution should yield an ideal solution; percentage stavudine recovered 
from the solution was the ratio of obtained to expected concentrations.
Fig. 1. Calibration curve for pure stavudine compound. The 
dotted line represents the best-fit linear curve (y=2678.121488 x 
–6.446728, R2=0.999915).
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by the opened capsule method is bioequivalent to a proprietary 
formulation approved by regulatory agencies.
In the future, paediatric fixed-drug combination (FDC) 
antiretroviral formulations will greatly accelerate the roll-out 
of antiretrovirals to children in rural resource-limited settings. 
However, no paediatric antiretroviral FDCs have as yet been 
registered in South Africa. Until FDCs become widely available 
in the public sector, clinicians should use the best available 
data when prescribing adult antiretroviral formulations in 
an off-label manner. However, studies that confirm adequate 
bioavailability and efficacy are needed.
Conclusion
Although the method of dispersing the contents of a capsule 
in water is off-label, and not condoned by the manufacturers 
of any of the three preparations, our findings suggest that the 
accuracy of the off-label opened capsule dosing method for 
stavudine dosing is acceptable. We have also shown that there 
may be no need to instruct caregivers to include sediment in 
the aliquot given to the infant. However, studies that confirm 
adequate bioavailability and efficacy are needed. Finally, it is 
important to use generic capsules whose contents disperse 
easily in water, as it may otherwise lead to a significant 
reduction in the amount of active drug that a child receives.
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